ReviewBreast care (Basel, Switzerland)2013
Genomic profiling in luminal breast cancer.
Review in Breast care (Basel, Switzerland), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- The clinicopathological and imaging parameters contributing to the similarity network fusion subtypes and prognosis of hormone receptor-positive HER2-negative breast cancer: an exploratory study.Quantitative imaging in medicine and surgery · 2026Article
- Risk Assessment Using Gene Expression Profiling Correlates with Clinical Prognosis Estimation in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer.Breast care (Basel, Switzerland) · 2025Article
- Identification of Patients with Early HR+ HER2- Breast Cancer at High Risk of Recurrence.Geburtshilfe und Frauenheilkunde · 2024Article
- Genomic Signatures in Luminal Breast Cancer.Breast care (Basel, Switzerland) · 2020Review
- Genomic Assays in Node Positive Breast Cancer Patients: A Review.Frontiers in oncology · 2020Review
- Extensive Transcriptomic and Genomic Analysis Provides New Insights about Luminal Breast Cancers.PloS one · 2016Article
- "Upstream Analysis": An Integrated Promoter-Pathway Analysis Approach to Causal Interpretation of Microarray Data.Microarrays (Basel, Switzerland) · 2015Article
- St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion.Breast care (Basel, Switzerland) · 2015Review
- Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics.Breast cancer research : BCR · 2015Review
- Bridging the gap - an update of translational research in breast cancer.Breast care (Basel, Switzerland) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The developments in gene expression analysis have made it possible to sub-classify hormone receptor-positive (luminal) breast cancer in different prognostic subgroups. This sub-classification is currently used in clinical routine as prognostic signature (e.g. 21-gene Onoctype DX®, 70-gene Mammaprint®). As yet, the optimal method for sub-classification has not been defined. Moreover, there is no evidence from prospective trials. This review explores widely used genomic signatures in luminal breast cancer, making a critical appraisal of evidence from retrospective/prospective trials. It is based on systematic literature search performed using Medline (accessed September 2013) and abstracts presented at the Annual Meeting of American Society of Clinical Oncology and San Antonio Breast Cancer Symposium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.